<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7345211\results\search\testTrace\results.xml">
  <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Validated and accurate laboratory" exact="testing" post="for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is"/>
  <result pre="Disease 2019 (COVID-19) disease, supporting the clinical decision-making process for" exact="infection" post="control at the healthcare level and detecting asymptomatic cases."/>
  <result pre="asymptomatic cases. This would facilitate an appropriate treatment, a prompt" exact="isolation" post="and consequently deceleration of the pandemic. Various laboratory tests"/>
  <result pre="COVID-19 pandemic. Johns Hopkins University reported over 7,600,000 cases of" exact="infection" post="and more than 427,000 deaths as of 13 June"/>
  <result pre="this rapidly progressing COVID-19 pandemic and the limited laboratory-based molecular" exact="testing" post="capacities, new point-of-care (POC), scalable rapid diagnostic tests have"/>
  <result pre="laboratory settings. What is more, the urgent need to multiply" exact="testing" post="for COVID-19 has been clearly identified as an essential"/>
  <result pre="specificity and accuracy concerning suspected COVID-19 infection, based on controlled" exact="testing" post="and performance data from clinical settings, is of substantial"/>
  <result pre="Unreliable and unproved tests may not detect patients with active" exact="infection" post="or may incorrectly indicate COVID-19-negative patients as positive, hampering"/>
  <result pre="reference tests based on molecular technique real-time quantitative reverse transcriptase" exact="polymerase chain reaction" post="assay (RT-qPCR) as well as serological antibody-detecting and antigen-detecting"/>
  <result pre="purposes. At present, only molecular quantitative reverse transcription PCR (RT-qPCR)" exact="testing" post="of respiratory tract samples is the recommended method for"/>
  <result pre="when the virus multiplies quickly, as this technique enables direct" exact="detection" post="of the pathogenâ€™s genetic material. A different approach in"/>
  <result pre="of the pathogenâ€™s genetic material. A different approach in diagnosing" exact="infection" post="is represented by serological methods, based on detectingâ€&quot;in blood"/>
  <result pre="should not be used as basis for diagnosing, ruling out" exact="infection" post="with SARS-CoV-2, or informing about infection status [6]. The"/>
  <result pre="for diagnosing, ruling out infection with SARS-CoV-2, or informing about" exact="infection" post="status [6]. The relatively quick discovery of the composition"/>
  <result pre="a substantial immunogenic ability and is abundantly expressed during viral" exact="infection" post="(Figure 1). The S/N proteins are targeted as potential"/>
  <result pre="develop new methods which will simplify and speed up the" exact="detection" post="of novel coronavirus. Currently, there are nearly 200 commercially"/>
  <result pre="In accordance with WHO recommendations, RT-qPCR tests must enable the" exact="detection" post="of three genes in a single reaction: E gene,"/>
  <result pre="provide the results in 2.5 h; it is a fast" exact="testing" post="kit for the Vivalytic platform. It is a fully"/>
  <result pre="for molecular laboratory diagnostics, with the option for various samples" exact="testing" post="and different analytical methods, can be carried out as"/>
  <result pre="2 h, i.e., three times faster than the presently quickest" exact="testing" post="methods, and which requires the application of relatively simple"/>
  <result pre="multiple infections (including Hepatitis C Virusâ€&quot;HCV and influenza) [16]. RNA" exact="detection" post="may be performed by means of RT-qPCR or reverse"/>
  <result pre="fast technology of DNA amplification, which is applied in the" exact="detection" post="of pathogens such as viruses or bacteria. LAMP reaction"/>
  <result pre="of taking clinical decisions and decrease the workload for centralized" exact="testing" post="laboratories [16]. POCT means that test results are instantly"/>
  <result pre="statement from the agency. The test was designed to provide" exact="detection" post="of novel coronavirus within a short period of 45"/>
  <result pre="bacterial or viral pathogens. The negative results do not exclude" exact="infection" post="and should not be the sole basis for patientsâ€™"/>
  <result pre="results when using the kit serve clinical purposes only. Clinical" exact="diagnosis" post="and treatment of patients should be considered in conjunction"/>
  <result pre="using the kit serve clinical purposes only. Clinical diagnosis and" exact="treatment" post="of patients should be considered in conjunction with the"/>
  <result pre="conjunction with the manifestations and symptoms, medical history, response to" exact="treatment" post="or other laboratory tests [9]. In general, the sensitivity"/>
  <result pre="bring an additional diagnostic value for accurate and quick COVID-19" exact="diagnosis" post="in vitro diagnostics, when the human body reacts to"/>
  <result pre="as well as the technical abilities and experience of the" exact="testing" post="unit. The validation of RT-qPCR tests seems to be"/>
  <result pre="The parameters describing those properties are known as limit of" exact="detection" post="(â€�LoDâ€�) and limit of quantification (â€�LoQâ€�). In many laboratories,"/>
  <result pre="amplification stage were carried out correctly. The failure in IPC" exact="detection" post="using a patientâ€™s specimen may indicate the improper extraction"/>
  <result pre="available, special attention should be paid to rapid lateral flow" exact="immunoassay" post="(LFIA), also referred to as immunochromatographic tests. Perhaps they"/>
  <result pre="time for obtaining results, and accelerate decision making regarding suitable" exact="treatment" post="[27,28,29]. 3.2. Immunoenzymatic and Immunofluorimetric Assays The detection of"/>
  <result pre="regarding suitable treatment [27,28,29]. 3.2. Immunoenzymatic and Immunofluorimetric Assays The" exact="detection" post="of specific SARS-CoV-2 serum antibodies allows for a rapid,"/>
  <result pre="antibodies allows for a rapid, cost-effective, and reasonably sensitive clinical" exact="diagnosis" post="of COVID-19, as immunoglobulins such as IgM provide the"/>
  <result pre="case of other viruses belonging to that family, while the" exact="detection" post="of IgG antibodies and IgM antibodies acting against SARS-CoV-2"/>
  <result pre="against SARS-CoV-2 may be an indication of infection. Moreover, the" exact="detection" post="of IgM antibodies usually indicates a recent exposure to"/>
  <result pre="antibodies usually indicates a recent exposure to SARS-CoV-2, whereas the" exact="detection" post="of IgG antibodies in case of COVID-19 indicates exposure"/>
  <result pre="result may be the evidence of past infection, not active" exact="infection" post="(Table 5). Negative results from serological tests do not"/>
  <result pre="results. This may be the case of past or ongoing" exact="infection" post="with virus strains other than SARS-CoV-2, such as coronavirus"/>
  <result pre="is of extreme importance, as it provides the possibility of" exact="testing" post="for antibodies in a material other than blood samples"/>
  <result pre="data concerning, among others, the dynamics of immunological response to" exact="infection" post="and the diagnostic value of available tests for detecting"/>
  <result pre="as a basic tool in diagnosing SARS-CoV-2 infections [32]. The" exact="detection" post="of specific anti-SARS-CoV-2 antibodies is possible about 10 days"/>
  <result pre="as it allows us to detect subjects who had the" exact="infection" post="but were asymptomatic or oligosymptomatic, and could have been"/>
  <result pre="asymptomatic or oligosymptomatic, and could have been the source of" exact="infection" post="for other people (â€œsilentâ€� carriers/vectors). It also allows us"/>
  <result pre="It also allows us to determine the spread of COVID-19" exact="infection" post="in the population. A comparative review of currently available"/>
  <result pre="Method (PMM) The protein microarray method (PMM) is a proteomic" exact="screening" post="technique serving the purpose of simultaneous/parallel quantitative and qualitative"/>
  <result pre="repeatability of the test itself, while the cost of the" exact="testing" post="and equipment used for micromatrix diagnostics is significant, which"/>
  <result pre="obtain COVID-19 diagnostic results and might support early implementation of" exact="isolation" post="resources and infection control measures. From a medical workforce"/>
  <result pre="results and might support early implementation of isolation resources and" exact="infection" post="control measures. From a medical workforce point of view,"/>
  <result pre="ultimately support public health strategies about the potential lifting of" exact="social distancing" post="restrictions in future [30]. Moreover, with the limited data"/>
  <result pre="contracting COVID-19, reducing the need for expensive reference molecular PCR" exact="testing" post="[4,6]. Finally, it is worth noting the psychological and"/>
  <result pre="demonstrates high sensitivity and specificity. In order to enable fast" exact="diagnosis" post="at the hospital or on admission, the test has"/>
  <result pre="when the nucleic acid of SARS-CoV-2 is found in the" exact="detection" post="system. In this way, a green signal of fluorescence"/>
  <result pre="online: http://www.ox.ac.uk/news/2020-03-18-oxford-scientists-develop-rapid-testing-technology-covid-19(accessed on 9 May 2020) 17.HuangW.E.LimB.HsuC.C.XiongD.WuW.YuY.JiaH.WangY.ZengY.JiM.et al.RT-LAMP for rapid" exact="diagnosis" post="of coronavirus SARS-CoV-2Microb. Biotechnol.20201395096110.1111/1751-7915.1358632333644 18.CuiZ.ChangH.WangH.LimB.HsuC.C.YuY.JiaH.WangY.ZengY.JiM.et al.Development of a rapid"/>
  <result pre="23.HsuehP.R.HuangL.M.ChenP.J.KaoC.L.YangP.C.Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after" exact="infection" post="with SARS-associated coronavirusClin. Microbiol. Infect.2004101062106610.1111/j.1469-0691.2004.01009.x15606632 24.GuanM.ChenH.Y.FooS.Y.TanY.J.GohP.Y.WeeS.H.Recombinant protein-based enzyme-linked immunosorbent"/>
  <result pre="Infect.2004101062106610.1111/j.1469-0691.2004.01009.x15606632 24.GuanM.ChenH.Y.FooS.Y.TanY.J.GohP.Y.WeeS.H.Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for" exact="detection" post="of immunoglobulin G antibodies to severe acute respiratory syndrome"/>
  <result pre="Immunol.20041128729110.1128/CDLI.11.2.287-291.2004 25.KogakiH.UchidaY.FujiiN.KuranoY.MiyakeK.KidoY.KariwaH.TakashimaI.TamashiroH.LingA.-E.et al.Novel rapid immunochromatographic test based on an enzyme" exact="immunoassay" post="for detecting nucleocapsid antigen in SARS-associated coronavirusJ. Clin. Lab."/>
  <result pre="weaknesses, opportunities and threatsA literature survey. Anal. Bioanal. Chem.200939356958210.1007/s00216-008-2287-218696055 29.StÃ¼renburgE.JunkerR.Point-of-care" exact="testing" post="in microbiology: The advantages and disadvantages of immunochromatographic test"/>
  <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ. Med. Virol.202010.1002/jmv.2572732104917 31.Independent Evaluations of COVID-19 Serological TestsAvailable"/>
  <result pre="(2019-nCoV) CE-IVD Star Array Ptd. Ltd. 8-min RT-qPCR direct PCR" exact="testing" post="RUO Veredus Laboratories VereCoVâ&quot;¢ Detection Kit and VerePLEXâ&quot;¢ CE-IVD"/>
  <result pre="BGI Health (HK) Co. Ltd. Real-time Fluorescent RT-PCR kit for" exact="detection" post="2019-nCOV (CE-IVD) ORF1 100% 99% 1â€&quot;10 bioMÃ©rieux ARGENEÂ® SARS-COV-2"/>
  <result pre="detect a specific disease P(+) N(âˆ’) N(âˆ’) Early stage of" exact="infection" post="P(+) P(+) N(âˆ’) Active phase of infection P(+) P(+)"/>
  <result pre="Early stage of infection P(+) P(+) N(âˆ’) Active phase of" exact="infection" post="P(+) P(+) P(+) Late or recurrent stage of infection"/>
  <result pre="of infection P(+) P(+) P(+) Late or recurrent stage of" exact="infection" post="P(+) N(âˆ’) P(+) Early stage of infection. PCR result"/>
  <result pre="result may be false negative * N(âˆ’) P(+) N(âˆ’) Past" exact="infection" post="(recover) * N(âˆ’) N(âˆ’) P(+) The recovery stage of"/>
  <result pre="result may be false negative * N(âˆ’) P(+) P(+) No" exact="infection" post="and no special symptoms N(âˆ’) N(âˆ’) N(âˆ’) P(+)â€&quot;positive; N(âˆ’)â€&quot;negative."/>
  <result pre="Specificity IgM+IgG 97.5% 97.1% 93.8% 100% Positive Predictive Value at" exact="prevalence" post="= 5% (IgM+IgG or IgG) 100% 67.8% 63.7% 42.4%"/>
  <result pre="IgG) 100% 67.8% 63.7% 42.4% 100% Negative Predictive Value at" exact="prevalence" post="= 5% (IgM+IgG or IgG) 99.5% 100% 99.8% 99.3%"/>
  <result pre="10â€&quot;15 Edinburgh Genetics Limited Watmind 2019 nCoV novel coronavirus antibody" exact="detection" post="reagent - - 10 Î¼L of serum or plasma;"/>
  <result pre="CE-IVD Edinburgh Genetics Limited Watmind 2019 nCoV novel coronavirus antibody" exact="detection" post="reagent CE-IVD Getein Biotech, Inc. One Step Test for"/>
 </snippets>
</snippetsTree>
